Figure 2
Kaplan-Meier plots for PFS and OS. (A) Progression-free survival (PFS): population-based evaluation, all patients (n = 54). (B) Overall survival (OS): population-based evaluation, all patients (n = 54). (C) PFS: population-based evaluation, patients treated with surgery alone (n = 19) versus patients treated with chemotherapy with or without surgery (n = 35); P < .001. (D) OS: population-based evaluation, patients treated with surgery alone (n = 19) versus patients treated with chemotherapy with or without surgery (n = 35); P < .001. (E) PFS: patients treated with IVE/MTX (n = 26) versus patients treated with anthracycline-based chemotherapy from population-based evaluation (n = 31); P = .01. (F) OS: patients treated with IVE/MTX (n = 26) versus patients treated with anthracycline-based chemotherapy from population-based evaluation (n = 31); P = .003

Kaplan-Meier plots for PFS and OS. (A) Progression-free survival (PFS): population-based evaluation, all patients (n = 54). (B) Overall survival (OS): population-based evaluation, all patients (n = 54). (C) PFS: population-based evaluation, patients treated with surgery alone (n = 19) versus patients treated with chemotherapy with or without surgery (n = 35); P < .001. (D) OS: population-based evaluation, patients treated with surgery alone (n = 19) versus patients treated with chemotherapy with or without surgery (n = 35); P < .001. (E) PFS: patients treated with IVE/MTX (n = 26) versus patients treated with anthracycline-based chemotherapy from population-based evaluation (n = 31); P = .01. (F) OS: patients treated with IVE/MTX (n = 26) versus patients treated with anthracycline-based chemotherapy from population-based evaluation (n = 31); P = .003

Close Modal

or Create an Account

Close Modal
Close Modal